B cell malignancies include lymphomas (Non-Hodgkin and Hodgkin), B cell leukemias (ALL, CLL) and multiple myeloma. Malignant B cells supplant normal bone marrow or lymphoid tissue and compromise bone marrow and immune function.
Although treatment options have improved greatly, many patients experience relapses and important subtypes are considered incurable. These cancers are associated with reduced quality of life, disease related morbidity (6-8% of cancer related deaths), and represents high societal as well as treatment costs.
The Centre is based on a multidisciplinary integration of life science research including drug discovery, design and innovation, molecular medicine, personalized medicine,ground breaking cell-based immunotherapy, as well as clinical trials and establishment of best practice on how to treat B-cell malignancies.
Our team includes molecular biologists, experts in in vivo mouse models, immunologists, cell biologists, bio-informaticians, and haematologists and oncologists with extensive experience in heading clinical trials.
We aim to strengthen the career-building opportunities for young scientists as aspiring new group leaders as well as heads of multicentre international clinical trials.
In line with the Horizon 2020 framework, we will perform Responsible Research and Innovation (RRI) with focus on public engagement and open access, gender, ethics, science education, and communication with stakeholders and institutions.
We therefore feel fortunate to include users and patients in planning and discussion of projects to democratize governance. We utilize open access dissemination and publications when possible.